Survival benefit of induction immunosuppression in cystic fibrosis lung transplant recipients

Stephen Kirkby, Bryan A. Whitson, Allison M. Wehr, Amy M. Lehman, Robert S. Higgins, Don Hayes

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Background: Despite resistant microbes, induction immunosuppression is used in patients with cystic fibrosis (CF) undergoing lung transplantation (LTx). Methods: To evaluate the effect of induction immunosuppression on survival, the United Network for Organ Sharing (UNOS) was queried restricting analysis to transplant patients 6-55. years old from 2001 to 2012, who received induction agents (INDUCED) or did not (NONE). Results: A total of 1721 CF patients who underwent LTx were included in the analysis; of these 791 (46%) were INDUCED. Of the INDUCED patients, 65% received basiliximab, 10% alemtuzumab, and 25% thymoglobulin/anti-lymphocyte globulin/anti-thymocyte globulin. Mean age was 28.0. years (SD. = 9.7) and 28.5 (SD. = 9.5) for the INDUCED and NONE groups, respectively. The median survival in the INDUCED group was 93.8. months (95% CI: 73.8, --) compared to 61.8. months (95% CI: 55.8-73.8) for the NONE group (log rank p-value <. 0.001). Conclusions: Antibody-based induction immunosuppression had a survival benefit in CF patients undergoing LTx.

Original languageEnglish (US)
Pages (from-to)104-110
Number of pages7
JournalJournal of Cystic Fibrosis
Issue number1
StatePublished - Jan 1 2015


  • Cystic fibrosis
  • Immunosuppression
  • Induction
  • Lung transplantation
  • Survival

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Survival benefit of induction immunosuppression in cystic fibrosis lung transplant recipients'. Together they form a unique fingerprint.

Cite this